• Explore /
  • Poster
  • / FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with <i>KRAS </i>and<i> NRAS</i> wild-type (wt) metastatic colorectal cancer (mCRC).

FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Thomas Brodowicz

Medical University of Vienna and Central European Cooperative Oncology Group, Vienna, Austria

Thomas Brodowicz , Damir Vrbanec , Klaus Kaczirek , Tudor-Eliade Ciuleanu , Regina Knittelfelder , Elisabeth Lindner , Diethelm Messinger , Christoph Zielinski , Berthold Streubel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Prevention, Diagnosis, and Screening

Clinical Trial Registration Number

NCT00479752

Citation

J Clin Oncol 32, 2014 (suppl 3; abstr LBA391^)

DOI

10.1200/jco.2014.32.3_suppl.lba391

Abstract #

LBA391^

Poster Bd #

A10

Abstract Disclosures

Similar Posters

First Author: Dalyong Kim

First Author: Stefan Kasper

First Author: Ann-Lii Cheng

First Author: Kelly S. Oliner